2018 AANS Annual Scientific Meeting-Metabolic and Endocrine Disorders in Pseudarthrosis

Video Transcription

Video Summary

Dr. Inam Khan, a research fellow at the Vanderbilt Spine Center, discusses metabolic and endocrine disorders in pseudoarthrosis in this late-breaking abstract. He highlights the increasing rates of spinal fusion surgery and the importance of understanding the risk factors and treatment for pseudoarthrosis, which accounts for approximately 23% of revision surgeries in the US. Factors contributing to non-union can be surgical, patient-related, or biological. The study analyzed 2,721 patients who underwent surgery for degenerative spine diseases, with 169 of them undergoing surgery for pseudoarthrosis. These patients were generally younger, had higher preoperative opioid use, and worse baseline disability index scores compared to the non-pseudoarthritic population. The study identified endocrine-related disorders in 82% of the pseudoarthritic patients, with osteoporosis being the most common, followed by vitamin D deficiency, diabetes, hyperlipidemia, hormone deficiency, and hypothyroidism. Some patients were referred to an endocrine bone specialist, and various interventions, such as anabolic agents and calcium supplementation, were initiated or modified. However, no conclusions could be drawn about the efficacy of these interventions or evidence-based recommendations for endocrine referrals due to limitations in patient numbers and surgical details. The study emphasizes the need for a comprehensive approach to understanding and treating endocrine and metabolic disorders in patients with pseudoarthrosis and recommends further research and protocol development. No additional credits were granted in the transcript.

Asset Caption

Inamullah Khan

Keywords

metabolic disorders

endocrine disorders

pseudoarthrosis

spinal fusion surgery

risk factors